Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?
Abstract BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in the pathogenesis of NAFLD/NASH. AIM: To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatment with 3 statins on NAFLD/NASH using 2 non-invasive scores [NAFLD Activity Score (NAS); Fibrosis-4 score (FIB-4)]. METHODS: During the mandatory annual medical check-up, military personnel underwent a clinical and laboratory evaluation. Participants with NAFLD/NASH were randomise...
Source: Current Vascular Pharmacology - October 15, 2020 Category: Drugs & Pharmacology Authors: Sfikas G, Psallas M, Koumaras C, Imprialos K, Perdikakis E, Doumas M, Giouleme O, Karagiannis A, Athyros VG Tags: Curr Vasc Pharmacol Source Type: research

Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
kov M PMID: 33032512 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 8, 2020 Category: Drugs & Pharmacology Authors: Muzurović E, Smolović B, Vujošević S, Petakov M Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study.
CONCLUSIONS: These preliminary results suggest that treatment with tolvaptan could improve early atherosclerosis and endothelial dysfunction markers and improve the mood in ADPKD patients (probably by the acting on endothelial cell and adipocyte V2 receptors). PMID: 32957887 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - September 16, 2020 Category: Drugs & Pharmacology Authors: Lai S, Mangiulli M, Perrotta AM, Gigante A, Napoleoni L, Cipolloni E, Mitterhofer AP, Gasperini ML, Muscaritoli M, Cianci R, Giovannetti A, Falco F, Mastroluca D, Mazzaferro S Tags: Curr Vasc Pharmacol Source Type: research

Role of nicotinic acetylcholine receptors in cardiovascular physiology and pathophysiology: current trends and perspectives.
Abstract Nicotinic acetylcholine receptors (nAChRs) comprise a large family of ligand-gated ion channels that have a broad distribution in neurons and non-neuronal cells throughout the body. Native nAChRs, activated by acetylcholine (ACh) endogenously, are involved in a variety of physiological and pathophysiological processes. They regulate processes necessary for network operations through neurotransmitter release, cell excitability and neuronal integration. Emerging evidence suggests that nAChRs are capable of regulating cardiovascular (CV) functions in a cell type-specific manner, through the nervous system an...
Source: Current Vascular Pharmacology - September 15, 2020 Category: Drugs & Pharmacology Authors: Deng J, Jiang H Tags: Curr Vasc Pharmacol Source Type: research

Rationale and Design of the ACS-BP Study: Prognostic Value of In-Hospital Blood Pressure and Indices of Atherosclerosis in Acute Coronary Syndromes.
CONCLUSION: The study results should clarify the role of these non-invasive tools in secondary risk stratification of such patients. PMID: 32819248 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 19, 2020 Category: Drugs & Pharmacology Authors: Koumelli A, Konstantinou K, Kasiakogias A, Dimitriadis K, Leontsinis I, Mantzouranis E, Tolis E, Fragkoulis C, Ntalakouras I, Thomopoulos C, Tousoulis D, Tsioufis C Tags: Curr Vasc Pharmacol Source Type: research

Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.
CONCLUSION: This updated network meta-analysis confirms that clopidogrel significantly decreases the risk of major adverse cardiovascular events compared with aspirin, without increasing bleeding risk. Clopidogrel should remain a mainstay of PAD treatment, at least in patients at higher bleeding risk. PMID: 32819249 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 19, 2020 Category: Drugs & Pharmacology Authors: De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C Tags: Curr Vasc Pharmacol Source Type: research

PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
Abstract BACKGROUND: Statins are the mainstay of treatment for low-density lipoprotein cholesterol (LDL-C) lowering, however, some patients cannot tolerate statins because of adverse effects. Ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are alternative treatment options. The purpose of this meta-analysis is to compare LDL-C reduction with ezetimibe vs PCSK9i in patients not on statins. METHODS: PubMed and EMBASE were searched until 14 March 2020 for randomized clinical trials (RCTs) assessing the efficacy of ezetimibe vs PCSK9i in patients not on statins. The primary outcome...
Source: Current Vascular Pharmacology - August 5, 2020 Category: Drugs & Pharmacology Authors: Benhuri B, Ueyama H, Takagi H, Briasoulis A, Kuno T Tags: Curr Vasc Pharmacol Source Type: research

Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases Part 2.
Abstract In Part 1 of this Thematic Issue entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", a panel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular complications of spondyloarthritides, rheumatoid arthritis, Sjogren's syndrome and vasculitides, as well as relevant cardiovascular issues related to non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), and provided their recommendations for prevention and management of these complications. In part 2 of this Thematic Issue, experts discuss the enhanced car...
Source: Current Vascular Pharmacology - July 20, 2020 Category: Drugs & Pharmacology Authors: Manolis AS, Tzioufas AG Tags: Curr Vasc Pharmacol Source Type: research

Obesity and gestational diabetes in pregnant care and clinical practice.
Abstract Obesity and Gestational Diabetes Mellitus (GDM) are the most frequent pathologies affecting mothers and offspring during pregnancy. Both conditions have shown a sustained increase in their prevalence in recent years, and they worsen the outcome of pregnancy and the long-term health of mothers. Obesity increases the risk of GDM and preeclampsia during pregnancy and elevates the risk of developing metabolic syndrome in later life. Offspring of obese mothers have an increased risk of obstetric morbidity and mortality and, consistent with the developmental origins of health and disease, a long term risk of ch...
Source: Current Vascular Pharmacology - June 27, 2020 Category: Drugs & Pharmacology Authors: Poblete JA, Olmos P Tags: Curr Vasc Pharmacol Source Type: research

The Innate Immune System And Cardiovascular Disease In Eskd: Monocytes And Natural Killer Cells.
Abstract Adverse innate immune responses have been implicated in several disease processes, including cardiovascular disease (CVD) and chronic kidney disease (CKD). The monocyte subsets natural killer (NK) cells and natural killer T (NKT) cells are involved in innate immunity. Monocytes subsets are key in atherogenesis and the inflammatory cascade occurring in heart failure. Upregulated activity and counts of pro-inflammatory CD16+ monocyte subsets are associated with clinical indices of atherosclerosis, heart failure syndromes and CKD. Advanced CKD is a complex state of persistent systemic inflammation characteri...
Source: Current Vascular Pharmacology - June 26, 2020 Category: Drugs & Pharmacology Authors: Dounousi E, Duni A, Naka KK, Vartholomatos G, Zoccali C Tags: Curr Vasc Pharmacol Source Type: research

Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions.
Abstract Obesity and gestational diabetes mellitus (GDM) are becoming more common among pregnant women worldwide and are individually associated with a number of placenta-mediated obstetric complications, including preeclampsia, macrosomia, intrauterine growth restriction and stillbirth. The placenta serves several functions throughout pregnancy and is the main exchange site for the transfer of nutrients and gas from mother to fetus. In pregnancies complicated by maternal obesity or GDM, the placenta is exposed to environmental changes, such as increased inflammation and oxidative stress, dyslipidemia, and altered...
Source: Current Vascular Pharmacology - June 15, 2020 Category: Drugs & Pharmacology Authors: Bedell S, Hutson J, de Vrijer B, Eastabrook G Tags: Curr Vasc Pharmacol Source Type: research

Efficacy and Safety of Evolocumab in Reducing Low Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
Abstract AIMS: To explore early intensive lipid-lowering therapy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). BACKGROUND: Lowering low-density lipoprotein cholesterol (LDL-C) levels can reduce cardiovascular morbidity and mortality in patients with atherosclerotic cardiovascular disease. Due to many reasons, the need for early intensive lipid-lowering therapy is far from being met in Chinese NSTE-ACS patients at high-risk of recurrent ischaemic events. OBJECTIVE: To evaluate the feasibility, safety and efficacy of starting evolocumab in hospital to lower LDL-C levels in C...
Source: Current Vascular Pharmacology - June 15, 2020 Category: Drugs & Pharmacology Authors: Xu X, Chai M, Cheng Y, Peng P, Liu X, Yan Z, Guo Y, Zhao Y, Zhou Y Tags: Curr Vasc Pharmacol Source Type: research

Herbal Medicine for Slowing Aging and Cardiovascular Risk: Mechanisms and Safety.
PMID: 32519621 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 12, 2020 Category: Drugs & Pharmacology Authors: Liu Y, Liu Y Tags: Curr Vasc Pharmacol Source Type: research

Response to Letter to the Editor by Briana and Malamitsi-Puchner: Effects of Pregnancy-induced Insulin Resistance on the Fetus and the Future Development of Metabolic Diseases in Adulthood.
ez CM PMID: 32519622 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 12, 2020 Category: Drugs & Pharmacology Authors: Mate A, Blanca AJ, Salsoso R, Toledo F, Stiefel P, Sobrevia L, Vázquez CM Tags: Curr Vasc Pharmacol Source Type: research

Paget's Disease of Bone and Cardiovascular Risk: a Pilot Study.
CONCLUSION: These findings, although limited by the small study population, represent an original observation that deserves further study. The higher arterial stiffness in PDB could be related to the increased bone turnover or to the high levels of oxidative stress that characterize this population. PMID: 32516100 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 8, 2020 Category: Drugs & Pharmacology Authors: Gaudio A, Zanoli L, Xourafa A, Rapisarda R, Catalano A, Signorelli SS, Castellino P Tags: Curr Vasc Pharmacol Source Type: research

Stromal Cell-Derived Factor (SDF) 2 and the Endoplasmic Reticulum Stress Response of Trophoblast Cells in Gestational Diabetes Mellitus and in vitro Hyperglycaemic Condition.
CONCLUSION: Our findings extend the understanding of ER stress and SDF2 expression in placentae exposed to hyperglycaemia, highlighting the relevance of insulin in reducing the levels of ER stress factors in placental cells. Understanding the effect of ER stress partners such as SDF2 on signalling pathways involved in gestation, complicated by hyperglycaemia, is pivotal for basic biomedical research and may lead to new therapeutic possibilities. PMID: 32504504 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 5, 2020 Category: Drugs & Pharmacology Authors: Lorenzon AR, Moreli JB, de Macedo Melo R, Namba FY, Staff AC, Yung HW, Burton GJ, Bevilacqua E Tags: Curr Vasc Pharmacol Source Type: research

Evaluation of Therapeutic Agents Targeting the Pathogenesis of Coronary Artery Spasm: A Mini Review.
This article discusses the pathophysiological mechanisms as well as downstream molecular pathways of CAS, with a focus on potential therapeutic targets. PMID: 32493195 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 2, 2020 Category: Drugs & Pharmacology Authors: Zhao X, Tian J, Ye Z, Xu M, Song X, Huang R Tags: Curr Vasc Pharmacol Source Type: research

Inflammasomes in the pathophysiology of maternal obesity: Potential therapeutic targets to reduce long-term adverse health outcomes in the mother and offspring.
Abstract Over the past 20 years, the prevalence of obesity has risen dramatically worldwide, with an increase in occurrence among women in their reproductive age. Obesity during pregnancy is associated with significantly increased maternal and fetal morbidity and mortality. In addition to the short-term adverse health outcomes, both mother and the child are prone to develop cardiovascular, metabolic and neurological disorders. Although associations between obesity during pregnancy and adverse maternal-fetal health outcomes are clear, the complex molecular mechanisms underlying maternal obesity remain largely unkno...
Source: Current Vascular Pharmacology - June 2, 2020 Category: Drugs & Pharmacology Authors: Murthi P, Rajaraman G Tags: Curr Vasc Pharmacol Source Type: research

Effects of Gentiana lutea root on vascular diseases.
CONCLUSION: Gentiana species and their constituents affect many different factors related to vascular disease development and progression. Therefore, Gentiana-based therapeutics represent potentially useful drugs for the management of vascular diseases. PMID: 32469702 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 28, 2020 Category: Drugs & Pharmacology Authors: Joksic G, Radak D, Sudar-Milovanovic E, Obradovic M, Radovanovic J, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Investigating the link between psoriasis and cardiovascular disease: current evidence, therapeutic implications and perspectives.
Abstract Psoriasis; a chronic inflammatory disease is characterized by symmetric hyperkeratotic plaques affecting any part of the body. Psoriasis is nowadays considered as a systemic inflammation linked with several comorbidities as metabolic syndrome, depression, anxiety and increased prevalence of cardiovascular (CV) disease. The hypothesis that psoriasis is an independent CV risk factor leading to atherosclerosis via inflammation. is now widely accepted. Deciphering the underlying mechanisms interconnecting psoriasis and CV disease may have significant implications on treatment decisions. Accumulating evidence ...
Source: Current Vascular Pharmacology - May 22, 2020 Category: Drugs & Pharmacology Authors: Kapniari E, Papadimitriou P, Dalamaga M, Makavos G, Piaserico S, Egeberg A, Ikonomidis I, Papadavid E Tags: Curr Vasc Pharmacol Source Type: research

Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class.
Conclusions BBs differ within the class in so many ways that it is not only logical but also practical for real-life clinical practice that experts in the field make a list of the compelling indications for individual BBs. Time has come to incorporate our knowledge about BBs into a new approach of presenting these useful and very individual drugs. PMID: 32418526 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 17, 2020 Category: Drugs & Pharmacology Authors: Koracevic G, Micic S, Stojanovic M, Lovic D, Simic D, Colic M, Koracevic M, Stojkovic A, Paunovic M Tags: Curr Vasc Pharmacol Source Type: research

Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
Abstract In the current Thematic Issue of Current Vascular Pharmacology (CVP), entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", presented in two parts, Part 1 and Part 2, review articles are included from specialists in cardiology, rheumatology, immunology and related fields. These reviews discuss the cardiovascular complications of the main systemic autoimmune rheumatic diseases (ARDs). For example, the underlying pathogenetic mechanisms, the role of cardiovascular imaging and recommendations for prevention and management. These articles place inflammation as the key process, linking ca...
Source: Current Vascular Pharmacology - May 13, 2020 Category: Drugs & Pharmacology Authors: Manolis AS, Tzioufas AG Tags: Curr Vasc Pharmacol Source Type: research

Effects of Maternal Obesity On Placental Phenotype.
Abstract The incidence of obesity is rising rapidly worldwide with the consequence that more women are entering pregnancy overweight or obese. This leads to an increased incidence of clinical complications during pregnancy and of poor obstetric outcomes. The offspring of obese pregnancies are often macrosomic at birth although there is also a subset of the progeny that are growth restricted at term. Maternal obesity during pregnancy is also associated with cardiovascular, metabolic and endocrine dysfunction in the offspring later in life. As the interface between the mother and fetus, the placenta has a central ro...
Source: Current Vascular Pharmacology - May 12, 2020 Category: Drugs & Pharmacology Authors: Fowden A, Camm E, Sferruzzi-Perri A Tags: Curr Vasc Pharmacol Source Type: research

Prime Time for Lower Extremity Artery Disease.
PMID: 32340598 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 30, 2020 Category: Drugs & Pharmacology Authors: De Carlo M Tags: Curr Vasc Pharmacol Source Type: research

Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?
PMID: 32340599 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 30, 2020 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Mantzoros C Tags: Curr Vasc Pharmacol Source Type: research

Endothelial dysfunction and inflammatory markers of vascular disease.
Abstract Vascular diseases are the main reason for morbidity and mortality worldwide. As we known, the earlier phase of vascular diseases is endothelial dysfunction in humans. The endothelial tissues play an important role in inflammation, coagulation, and angiogenesis, via the organizing of ligand-receptor associations and the various mediators' secretion. We can use many inflammatory non-invasive tests (flow-mediated dilatation, epicedial fat thickness, carotid-intima media thickness, arterial stiffness and ankle-brachial index) for assessing the endothelial function. In addition, many biomarkers (ischemia modif...
Source: Current Vascular Pharmacology - April 20, 2020 Category: Drugs & Pharmacology Authors: Balta S Tags: Curr Vasc Pharmacol Source Type: research

New insights into the role of FGF-23 and Klotho in cardiovascular disease in chronic kidney disease patients.
Abstract Alterations of fibroblast growth factor 23 (FGF-23) and Klotho levels are considered to be the earliest biochemical abnormality of chronic kidney disease - mineral and bone disease (CKD-MBD) syndrome. Moreover, emerging data suggests that the dysregulated FGF-23 and Klotho axis has many effects on the cardiovascular (CV) system and contributes significantly to the increased CV morbidity and mortality rates of CKD patients. This review examines recent evidence on the role of FGF-23 and Klotho in the development and progression of CV complications of uremia namely cardiac hypertrophy, uremic cardiomyopathy ...
Source: Current Vascular Pharmacology - April 18, 2020 Category: Drugs & Pharmacology Authors: Memmos E, Papagianni A Tags: Curr Vasc Pharmacol Source Type: research

The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy - The Piece of a Much Larger Puzzle.
CONCLUSIONS: Predictive value of GFR CKD-EPI and creatinine concentration for a positive response to CRT were found relevant. PMID: 32286948 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 12, 2020 Category: Drugs & Pharmacology Authors: Dębska-Kozłowska A, Warchoł I, Książczyk M, Lubiński A Tags: Curr Vasc Pharmacol Source Type: research

Erectile dysfunction as a cardiovascular risk factor: time to step up?.
CONCLUSION: Accumulating evidence supports a strong predictive role of ED for CV events. Early identification of ED could allow for the optimal management of these patients to reduce the risk for a CV event to occur. PMID: 32286949 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 12, 2020 Category: Drugs & Pharmacology Authors: Imprialos K, Koutsampasopoulos K, Manolis A, Doumas M Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular disease in Juvenile Idiopathic Arthritis.
Abstract Juvenile idiopathic arthritis (JIA), is a term used to describe a group of inflammatory disorders beginning before the age of 16 years. Although for the majority of children remission is achieved early, those with systemic or polyarticular form of the disease may present persistent symptoms in adulthood. Considering that there is overlap in the pathogenesis of JIA with adult rheumatic diseases, concerns have been raised as to whether JIA patients could be at increased cardiovascular (CV) risk in the long-term. In this review, we summarize evidence for CV involvement in JIA and present data on CV risk fact...
Source: Current Vascular Pharmacology - April 7, 2020 Category: Drugs & Pharmacology Authors: Arsenaki E, Georgakopoulos P, Mitropoulou P, Koutli E, Thomas K, Charakida M, Georgiopoulos G Tags: Curr Vasc Pharmacol Source Type: research

Pulse wave velocity assessment for cardiovascular risk prognostication in ESKD: weighing recent evidence.
CONCLUSION: Despite the strong pathophysiological relevance of arterial stiffness as a mediator of CV disease in ESKD, the assessment of aortic PWV for CV risk stratification in this population appears to be of limited value. Whether aortic PWV assessment is valuable in guiding CV risk factor management and whether such a therapeutic approach is translated into improvement in clinical outcomes is an issue of clinical relevance that warrants investigation in properly-designed randomized trials. PMID: 32242783 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 2, 2020 Category: Drugs & Pharmacology Authors: Georgianos PI, Vaios V, Eleftheriadis T, Zebekakis PE, Liakopoulos V Tags: Curr Vasc Pharmacol Source Type: research

Coronary Calcium Risk Score and Cardiovascular Risk.
Abstract The association between presence of coronary artery calcium (CAC) and risk of coronary artery disease (CAD) has been appreciated for decades. In this review, we critically appraise the role of CAC based on computerized tomography in contemporary risk stratification. Available evidence suggests that measurement of CAC is a useful modality in many patients for more precise risk stratification and prognostic determination. Whether newer CAC score incorporating extra coronary calcification, will add incremental value, especially for stroke and other non-coronary vascular outcomes needs prospective study. ...
Source: Current Vascular Pharmacology - April 2, 2020 Category: Drugs & Pharmacology Authors: Lehker A, Mukherjee D Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis.
Abstract Hemodialysis (HD) remains the most utilized treatment for End Stage Kidney Disease (ESKD) globally, mainly as conventional HD administered in 4 h sessions thrice weekly. Despite advances in HD delivery, patients with ESKD carry a heavy cardiovascular morbidity and mortality burden. This is associated with cardiac remodeling, left ventricular hypertrophy (LVH), myocardial stunning, hypertension, decreased heart rate variability, sleep apnea, coronary calcification and endothelial dysfunction. Therefore, intensive HD regimens closer to renal physiology were developed. They include longer, more frequent dial...
Source: Current Vascular Pharmacology - March 31, 2020 Category: Drugs & Pharmacology Authors: Roumeliotis A, Roumeliotis S, Chan C, Pierratos A Tags: Curr Vasc Pharmacol Source Type: research

Lifestyle, maternal nutrition and healthy pregnancy.
te;zquez CM Abstract Healthy lifestyle habits spanning from preconception to postpartum are considered as a major safeguard for achieving successful pregnancies and for prevention of gestational diseases. Among preconception priorities established by the World Health Organization (WHO) are healthy diet and nutrition, weight management, physical activity, planned pregnancy and physical, mental and psychosocial health. Most studies covering the topic of healthy pregnancies focus on maternal diet because obesity increases the risks for adverse perinatal outcomes, including gestational diabetes mellitus, large for ges...
Source: Current Vascular Pharmacology - March 31, 2020 Category: Drugs & Pharmacology Authors: Mate A, Reyes-Goya C, Santana-Garrido Á, Vázquez CM Tags: Curr Vasc Pharmacol Source Type: research

The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes.
Abstract Hypertension is a powerful risk factor for cardiovascular morbidity and mortality. High blood pressure (BP) correlates closely with all-cause and cardiovascular mortality. Although the gold standard still remains office BP (auscultatory or automated), other methods (central or out-of-office) are gaining popularity as better predictors of CV events. In this review, we investigated the prognostic value of each method of BP measurement and explored their advantages and pitfalls. Unattended automated office BP is a novel technique of BP measurement with promising data. Ambulatory BP monitoring, and to a lesse...
Source: Current Vascular Pharmacology - March 29, 2020 Category: Drugs & Pharmacology Authors: Bakogiannis C, Stavropoulos K, Papadopoulos C, Papademetriou V Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Complications of Sleep Disorders: A Better Night's Sleep for a Healthier Heart / From Bench to Bedside.
Abstract Sleep is essential to and an integral part of life and when lacking or disrupted, a multitude of mental and physical pathologies ensue, including cardiovascular (CV) disease, which increase health care costs. Several prospective studies and meta-analyses show that insomnia, short (9h) sleep and other sleep disorders are associated with an increased risk of hypertension, metabolic syndrome, myocardial infarction, heart failure, arrhythmias, CV disease risk and/or mortality. The mechanisms by which insomnia and other sleep disorders lead to increased CV risk may encompass inflammatory, immunological, neuro-...
Source: Current Vascular Pharmacology - March 23, 2020 Category: Drugs & Pharmacology Authors: Manolis TA, Manolis AA, Apostolopoulos E, Melita H, Manolis AS Tags: Curr Vasc Pharmacol Source Type: research

Metabolic adaptations to pregnancy in healthy and gestational diabetic pregnancies: the pancreas - placenta axis.
METABOLIC ADAPTATIONS TO PREGNANCY IN HEALTHY AND GESTATIONAL DIABETIC PREGNANCIES: THE PANCREAS - PLACENTA AXIS. Curr Vasc Pharmacol. 2020 Mar 20;: Authors: Hill D, Szlapinski SK Abstract Normal pregnancy is associated with increased insulin resistance as a metabolic adaptation to the nutritional demands of the placenta and fetus, and this is amplified in obese mothers. Insulin resistance is normally compensated for by an adaptive increase in pancreatic β-cell mass together with enhanced glucose-stimulated insulin release. Placentally-derived hormones and growth factors are central to the altere...
Source: Current Vascular Pharmacology - March 19, 2020 Category: Drugs & Pharmacology Authors: Hill D, Szlapinski SK Tags: Curr Vasc Pharmacol Source Type: research

Vitamin K for the treatment of cardiovascular disease in End-Stage Renal Disease patients: is there hope?
Abstract In Chronic Kidney Disease, vascular calcification (VC) is highly prevalent even at early stages and is gradually enhanced, along with disease progression to End-Stage Renal Disease (ESRD). The calcification pattern in uremia includes all types of mineralization and contributes to the heavy cardiovascular (CV) burden that is common in these patients. Ectopic mineralization is the result of the imbalance between inhibitors and promoters of vascular calcification, with the latter overwhelming the former. The most powerful, natural inhibitor of calcification is Matrix Gla Protein (MGP), a small vitamin K depe...
Source: Current Vascular Pharmacology - March 19, 2020 Category: Drugs & Pharmacology Authors: Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V Tags: Curr Vasc Pharmacol Source Type: research

The Neuro-Vascular Consequence of Diabetes: Foot Amputation and Evaluation of its Risk Factors and Health-Related Economic Impact.
This study aimed to determine financial burden and risk factors associated with T2DM-related foot amputation. METHODS: Retrospective hospital-based study from January 2017 to December 2018. Patients with T2DM with and without amputation were enrolled. The direct medical costs of amputation along with various risk factors were determined. Risk factors were evaluated by logistic regression analysis. RESULTS: A total 1460 patients with T2DMwere included; 484 (33%) patients had an amputation. Mean total cost of below knee, fingers and toe amputation were 886.63±23.91, 263.35 ±19.58 and 166.68 ± 8...
Source: Current Vascular Pharmacology - March 19, 2020 Category: Drugs & Pharmacology Authors: Naqvi IH, Talib A, Naqvi SH, Yasin L, Rizvi NZ Tags: Curr Vasc Pharmacol Source Type: research

Non-Alcoholic Fatty Liver Disease and Vascular Disease.
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It is globally-projected that NAFLD will become increasingly prevalent, especially among children and younger adults. As such, even within the next few years, NAFLD will contribute considerably to the overall CVD burden. In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, this ar...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Manousou P, Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz M Tags: Curr Vasc Pharmacol Source Type: research

Inflammatory markers in cardiovascular disease; lessons learned and future perspectives.
CONCLUSION: There is significant evidence regarding the role of consolidated and novel inflammatory markers in the field of diagnosis and prognosis of CVD. However, multimarker model assessment, validation of cut-off values and cost-effectiveness analyses are required, in order for those markers to be integrated into daily clinical practice. PMID: 32188386 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Grassos H, Doumas M, Faselis C Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular disease in patients with chronic obstructive pulmonary disease, obstructive sleep apnoea syndrome and overlap syndrome.
Abstract Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea syndrome (OSAS) are among the most prevalent chronic respiratory disorders. Accumulating data suggest that there is a significant burden of cardiovascular disease (CVD) in patients with COPD and OSAS, affecting negatively patients' quality of life and survival. Overlap syndrome (OS), i.e. the co-existence of both COPD and OSAS in the same patient, has an additional impact on cardiovascular system multiplying the risk of morbidity and mortality. The underlying mechanisms for the development of CVD in patients with either OSAS or COPD...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Voulgaris A, Archontogeorgis K, Steiropoulos P, Papanas N Tags: Curr Vasc Pharmacol Source Type: research

Prognostic significance of relative hyperglycemia after percutaneous coronary intervention in patients with and without recognized diabetes.
Abstract BACKGROUND: The research on the association between relative glycemic level post-percutaneous coronary intervention (PCI) and adverse prognosis in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients is relatively inadequate. OBJECTIVE: To identify whether the glycemic level post-PCI predicts adverse prognosis in NSTE-ACS patients. METHODS: Patients (n=2465) admitted with NSTE-ACS who underwent PCI were enrolled. The relative glycemic level post-procedure was calculated as blood glucose level post-PCI divided by HbA1c level, which was named post-procedural glycemic index (PGI). T...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Zhao Q, Zhang T, Cheng Y, Ma Y, Xu Y, Yang J, Zhou Y Tags: Curr Vasc Pharmacol Source Type: research

Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i.
Abstract Type 2 diabetes mellitus (T2DM) is a rapidly evolving global health issue associated with a markedly increased risk of cardiovascular (CV) morbidity and mortality. The hyperglycaemic milieu contributes to the development of CV complications via several pathological pathways, leading to increased arterial stiffness (AS), that can be considered as a predictor of CV events in patients with diabetes. The measurement of AS is increasingly used for the clinical assessment of patients. Several methodologies were used in large population studies to assess AS; the most commonly used is the pulse wave velocity (PWV...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Lamacchia O, Sorrentino MR Tags: Curr Vasc Pharmacol Source Type: research

Antihypertensive therapy in patients receiving maintenance hemodialysis: a narrative review of the available clinical-trial evidence.
CONCLUSION: Our first-line therapy of hypertension in hemodialysis is the assessment and management of dry-weight and optimization of dialysis prescription. Based on the available clinical-trial evidence, we prescribe atenolol 3 times/week after dialysis as first-line pharmacological option of hypertension to our patients without specific indications for other agents. Long-acting dihydropyridines and ACEIs/ARBs are our second-line and third-line choices, respectively. We avoid using MRAs and await results from ongoing trials testing their safety and efficacy. In patients receiving maintenance hemodialysis, randomized trial...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Georgianos P, Agarwal R Tags: Curr Vasc Pharmacol Source Type: research

Could antioxidant supplementation delay progression of cardiovascular disease in end-stage renal disease patients?
Abstract In end-stage renal disease patients the leading causes of mortality are of cardiovascular origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. Notwithstanding, a contributing role of oxidative stress is postulated, which is increased even at early stages of chronic kidney disease, is gradually augmented in parallel to its progression to end-stage renal disease and is further accelerated by renal replacement therapies. Oxidative stress ensues when there is an imbalance between reactive pro-oxidants and physiologically occurring, ele...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Roumeliotis S, Roumeliotis A, Gorny X, Mertens P Tags: Curr Vasc Pharmacol Source Type: research

Vitamin D and vascular disease.
Abstract Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Vitamin D deficiency has been identified as a potential risk factor for a number of diseases unrelated to the classical skeletal pathophysiology, such as cancer and CVD, but the effects of vitamin D supplementation are less clear. Purpose of this narrative review is to discuss the evidence suggesting an association between vitamin D status and CVD as well as the results of supplementation studies. Vitamin D deficiency has been associated with CVD risk factors such as hypertension, dyslipidemia and diabetes mellitus as well...
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Gouni-Berthold I, Berthold HK Tags: Curr Vasc Pharmacol Source Type: research

LncRNA MALAT1 Enhances ox-LDL-Induced Autophagy through the SIRT1/MAPK/NF- κB Pathway in Macrophages.
CONCLUSION: LncRNA MALAT1 Enhances Ox-LDL-induced Autophagy via the SIRT1/MAPK/NF-κB Pathway in Macrophages. PMID: 32183682 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 16, 2020 Category: Drugs & Pharmacology Authors: Yang J, Lin X, Wang LA, Sun T, Zhao Q, Ma Q, Zhou Y Tags: Curr Vasc Pharmacol Source Type: research

Fetal/Infant Origins of Adult Vascular Disease.
PMID: 32129165 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 3, 2020 Category: Drugs & Pharmacology Authors: Paraskevas KI, Briana DD, Malamitsi-Puchner A, Mikhailidis DP Tags: Curr Vasc Pharmacol Source Type: research

Assessment and management of volume overload among patients on chronic dialysis.
Abstract Volume overload is the most common complication in end-stage renal disease (ESRD) patients, being directly related to numerous complications including resistant hypertension, cardiac hypertrophy, congestive heart failure or arterial stiffness, among others. Therefore, volume overload is now considered an important risk factor for hard outcomes, like all-cause or cardiovascular mortality. Relying solely on clinical examination for assessing volume overload in ESRD patients lacks sensitivity and specificity. Numerous efforts have been made to identify new methods that could objectively assess volume status;...
Source: Current Vascular Pharmacology - February 23, 2020 Category: Drugs & Pharmacology Authors: Covic A, Siriopol D Tags: Curr Vasc Pharmacol Source Type: research